The cohort included 5 Vκ*MYC mice without detectable disease (early-MM, EMM1-5, 27–33 weeks), 3 Vκ*MYC mice with intermediate disease (int-MM, IMM1-3, 49 weeks), and 7 Vκ*MYC mice with active MM (active-MM, AMM1-7, 61−74 weeks). This evidence concerns the gene MYC and Miyoshi myopathy.